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Mitofusin-2 (MFN2) is a dynamin-like GTPase that plays a central role in regulating mito-
chondrial fusion and cell metabolism. Mutations in MFN2 cause the neurodegenerative dis-
ease Charcot-Marie-Tooth type 2A (CMT2A). The molecular basis underlying the
physiological and pathological relevance of MFN2 is unclear. Here, we present crystal
structures of truncated human MFN2 in different nucleotide-loading states. Unlike other
dynamin superfamily members including MFN1, MFN2 forms sustained dimers even after
GTP hydrolysis via the GTPase domain (G) interface, which accounts for its high membrane-
tethering efficiency. The biochemical discrepancy between human MFN2 and MFN1 largely
derives from a primate-only single amino acid variance. MFN2 and MFN1 can form hetero-
dimers via the G interface in a nucleotide-dependent manner. CMT2A-related mutations,
mapping to different functional zones of MFN2, lead to changes in GTP hydrolysis and homo/
hetero-association ability. Our study provides fundamental insight into how mitofusins
mediate mitochondrial fusion and the ways their disruptions cause disease.
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M itochondria are double-membrane organelles withvarying shapes influenced by metabolic conditions,developmental stage, and environmental stimuli1–3.
Their highly dynamic morphology is realized through regulated
and balanced fusion and fission processes4,5. Fusion is important
for the health and physiological functions of mitochondria,
including complementation of damaged mitochondrial DNAs
and maintenance of membrane potential5,6. Outer mitochondrial
membrane (OMM) fusion is catalyzed by the dynamin-like
GTPase called mitofusin (MFN)7,8. Mammals have two broadly
expressed and essential mitofusins, namely MFN1 and MFN2.
The two mitofusins share ~80% sequence similarity, and display a
certain grade of functional redundancy in mice9,10.
Despite the similarities, MFN1 and MFN2 are also reported in an
in vitro study to play distinct roles in mediating mitochondrial
fusion via GTPase activity11. Compared with MFN1, MFN2 seems
more versatile, and is frequently related to human diseases. MFN2
is proposed to regulate ER–mitochondria juxtaposition12,13. During
the mitophagy process, MFN2 is reported to be phosphorylated by
mitochondrial PTEN-induced putative kinase 1, and then recog-
nized by Parkin for culling damaged mitochondria14–16. Functions
of MFN2 have also been suggested in several other cellular pro-
cesses including ER stress, axonal transport, and cell cycle pro-
gression17–21. Mutations inMFN2, but notMFN1, cause most cases
of Charcot–Marie–Tooth type 2A (CMT2A) disease, an incurable
inherited neuromuscular disorder22. Emerging evidence suggests
that abnormal expression of MFN2 is also associated to the onset of
many other human diseases including Alzheimer’s disease, Par-
kinson’s disease, cardiomyopathy, diabetes, and cancer23–30. How-
ever, the structural basis for the functional diversity and
pathophysiological relevance of human MFN2 remains unclear.
Our recent structural studies of truncated MFN1 revealed a
typical dynamin-like domain organization of mitofusins, and pro-
posed a model for mitochondrial tethering involving intermolecular
(trans) association of G domains and subsequent GTP hydrolysis-
induced power stroke31–33. Although the overall architecture of
MFN2 is expected to be similar as that of MFN1, the current
information is still insufficient to explain the functional discrepancy
of the two mitofusins. Thus, a detailed structural analysis of MFN2
is critical to pinpoint the crucial differences between the two
mitofusins on the molecular level. In addition, MFN2 and MFN1
are shown to physically contact each other in cells, and this hetero-
association may play an important role in mediating mitochondrial
fusion and ER–mitochondria tethering9,13,34, but the molecular
basis of their interaction has yet to be elucidated.
In this study, we address these issues by presenting crystal
structures of truncated human MFN2 in different stages of the GTP
turnover cycle. These structures explain how MFN2 uses a primate-
only single amino acid variance and a tighter G interface, as
compared with human MFN1, to allow for enduring GTPase (G)
domain association even after GTP hydrolysis, a feature that is
unique in the dynamin superfamily and ensures efficient membrane
tethering. We also found that MFN2 is able to bind MFN1 via the G
interface and performs domain rearrangement in a nucleotide-
dependent manner. The structures of MFN2 enable us to visualize
most of the CMT2A-related mutations in a three-dimensional
landscape, and explain the unexpected diverse biochemical phe-
notypes of these mutants and mechanisms of MFN2-related
CMT2A onset. Overall, out study greatly contributes to the
understanding of MFN2-mediated cellular activities and the ways
its disruption cause disease.
Results
Overall structure of truncated MFN2. We generated a modified
human MFN2 construct with deletions of residues 1–21 and
401–705 (MFN2IM). When purified from Escherichia coli,
MFN2IM was loaded with GTP or GDP, which could be
removed by an optimized purification protocol (Supplementary
Fig. 1a, b). We determined crystal structures of MFN2IM in the
nucleotide-free and GDP-bound forms at 2.8 and 2.0 Å,
respectively (Fig. 1a, b, Table 1). MFN2IM contains a G domain
and a helical domain 1 (HD1). HD1 is connected to the G
domain via the so-called hinge 2, namely Arg95 at the C-
terminal end of α2H, and Lys357 between α5G and α3H
(Fig. 1c). The G domain consists of a central nine-stranded β-
sheet (β1G–β6G and β1′G–β3′G) surrounded by seven ɑ-helices
(ɑ1G–ɑ5G, ɑ1′G, and ɑ2′G) and two 310-helices (η1G and η2G),
of which β2′G and η1G are not observed for MFN1IM (Sup-
plementary Fig. 2a). Unlike MFN1, MFN2IM has a disordered
switch I in the nucleotide-free state, and the Trp260 does not
occupy the nucleotide-binding pocket (Fig. 1d). The four-
helical-bundle HD1 is stabilized by a massive hydrophobic
network (Supplementary Fig. 2b). ɑ4H, which comprises large
portion of the conventional HR2, is substantially involved in
this network. The C-terminal tip of ɑ4H physically contacts the
G domain (Fig. 1e, Supplementary Fig. 2c). With more residues
preserved than in the crystallized MFN1IM construct32, ɑ3H and
ɑ4H are extended in MFN2IM (Fig. 1b, Supplementary Fig. 2d).
A recently predicted MFN2 model proposed intramolecular
interactions for Met376-Leu727, and for His380-Asp725
between ɑ3H and ɑ4H 35. In our crystal structures, however,
Met376 is surrounded by Phe56, Leu57, and Leu734 from the
neighboring helices, and separated from Leu727. His380 and
Asp725 are both on the surface, but their side chains are not
close enough to form a salt bridge (Supplementary Fig. 2e).
We tested the association of nucleotide-free MFN2IM and
MFN1IM with different guanine nucleotides by isothermal
titration calorimetry (ITC). MFN2IM showed much higher affinity
to GTPγS and GDP compared with MFN1IM, and could
efficiently bind to GMPPNP (Fig. 1f, Supplementary Fig. 2f).
The stronger nucleotide association of MFN2IM may be partly
explained by the aforementioned conformational variance to
MFN1IM: the disordered switch I and outwardly oriented Trp260
leave an empty pocket that facilitates nucleotide docking
(Fig. 1d).
Thr111 in the P-loop of MFN2 has been reported to be a
phosphorylation site16. To investigate how Thr111 phosphoryla-
tion affects the function of MFN2, we solved the crystal structure
of a phosphorylation mimic MFN2IM(T111D) (Supplementary
Fig. 3a). According to the structure, the side chain of Asp111 is
not fully exposed, and its phosphorylation may require a
substantial local conformational rearrangement. Phosphorylated
Thr111, as reflected by the Asp111 in the crystal structure, blocks
the binding groove for GTP in the P-loop, and the negative
charge is also disfavored for the phosphate groups of the
nucleotide (Supplementary Fig. 3b). Subsequent ITC analysis
confirmed that MFN2IM(T111D) has no binding affinity to
guanine nucleotides (Supplementary Fig. 3c). Therefore, the
putative phosphorylation at Thr111 is likely to directly inactivate
MFN2 in mediating mitochondrial fusion. Intriguingly, we
observed calcium ions (Ca2+) associated with the HD1 of both
nucleotide-free wild-type MFN2IM and MFN2IM(T111D), and
one of them is involved in intermolecular contact (Supplementary
Fig. 3d). Addition of Ca2+ did not alter the biochemical features
of wild-type MFN2IM or MFN2IM(T111D) (Supplementary
Fig. 3e, f).
MFN2IM is an extremely weak GTPase. Previous study showed
that at low protein concentration (~0.06 μM), human MFN2 has
eightfold lower GTPase activity than MFN1 in the presence of
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mild detergent11. We compared the GTP turnover rates between
MFN2IM and MFN1IM at different protein concentrations.
MFN1IM showed stimulated GTP turnover, and the maximum
kcat exceeded 7 min−1 in the presence of 150 mM KCl. In con-
trast, the GTP turnover of MFN2IM remained less than 0.4 min−1
regardless of increasing protein concentrations in the same con-
dition (Fig. 2a). This huge difference in GTPase activity prompted
us to check the GDP off-rates of MFN1IM and MFN2IM by fast
kinetics analysis. In stopped-flow experiments, the GDP off-rate
for MFN2IM was slower than that of MFN1IM by 13-fold (Fig. 2b).
Thus, the weak GTPase activity of MFN2 can be partly explained
by the less efficient nucleotide exchange, which is also in agree-
ment with its higher binding affinity to guanine nucleotides
(Fig. 1f)
We then investigated the reasons for these differences between
the two homologs. Human MFN1 and MFN2 bear several
different residues in the P-loop and switch I, namely MFN2-
Asn107/MFN1-Ser86, MFN2-Thr111/MFN1-Ser90, and MFN2-
Thr129/MFN1-Ile108 (Fig. 2c). We individually swapped corre-
sponding residues between MFN1IM and MFN2IM, and applied
these mutants to GTP hydrolysis assays. MFN2IM(T129I) strongly
promoted GTP turnover by ~11-fold, while MFN1IM(I108T)
showed a 12-fold decrease (Fig. 2d). The other two swapping
pairs, by contrast, did not significantly alter the GTPase activity of
their wild-type counterparts (Supplementary Fig. 4a). Interest-
ingly, rodent MFN1 and MFN2 both have a threonine at the
corresponding position in switch I (Fig. 2c, Supplementary
Fig. 4b). Mouse MFN1IM and MFN2IM showed weak GTPase
hydrolysis similar to human MFN1IM(I108T) and human
MFN2IM, respectively (Fig. 2d). These results suggest that the
MFN2-Thr129/MFN1-Ile108 difference in switch I is a key
determinant for the incongruent GTPase activity of human
mitofusins.
We have previously reported that MFN1-Ile108 is involved in a
hydrophobic cluster that stabilizes switch I in a nucleotide-
occluding conformation32. The cluster is apparently disfavored by
the Thr129 exchange in MFN2, which endows the observed
flexibility to switch I in the nucleotide-free state (Supplementary
Fig. 4c). This idea was supported by the fact that T129I swapping
in MFN2IM slightly reduced binding affinity to GTPγS and GDP,
and increased GDP off-rate, whereas MFN1IM(I108T) led to
opposite outcome (Fig. 2e, Supplementary Fig. 4d). This
moderate influence, however, seems insufficient to explain the
large variance in the GTPase activity between MFN1 and MFN2.
In addition, we noticed that in all ITC results of MFN2IM,
including MFN2IM(T129I), the N values (indicating numbers of
binding site) are between 0.5 and 1, whereas for MFN1IM samples
the N values are all ranged from 1 to 1.5 (Fig. 1f, Supplementary
Figs. 2f, 4d). For MFN1IM constructs, the larger apparent N values
might be derived from the conformation rearrangement of the
Trp260 switch and switch I required for nucleotide loading32, but
this does not explain the smaller N values of MFN2IM in ITC
experiments. Thus, there may be other factors that define the
GTP turnover efficiency of human mitofusins, such as the
dimerization of the GTPase domains.
MFN2IM remains dimerized after GTP hydrolysis. Dynamin
superfamily members including MFN1, are known to form
functional G domain-mediated dimers in a nucleotide-dependent
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manner32,36–38. As revealed by right-angle light scattering
(RALS), MFN2IM stayed monomeric in the nucleotide-free (apo)
and GDP/GTPγS/GMPPNP-loading states, and formed stable
dimers in the presence of GTP or GDPBeF3 (Supplementary
Fig. 5a). The MFN2IM-GTP dimers were sustained after further
incubation while the GTP was slowly hydrolyzed to GDP (Sup-
plementary Fig. 5b). For the MFN2IM crystals that yielded the
GDP-bound structure, the GDP was not added during purifica-
tion or crystallization, but co-purified from the host E. coli cells
(Supplementary Fig. 1a). Somewhat unexpectedly, this GDP-
bound MFN2IM forms a G domain-mediated dimer across the
asymmetric units of the crystal lattice (Fig. 3a and Table 1). RALS
analysis revealed that the majority of freshly purified MFN2IM
molecules were indeed in the dimeric form (Supplementary
Fig. 5c). These observations indicate that MFN2IM dimerizes
during GTP hydrolysis, and the dimer remained associated after
the reaction. In the crystal structure, two citrate ions were present
between the associated G domains, and making contacts with
both of them in a symmetrical manner (Supplementary Fig. 5d,
e). In solution, however, citrate did not affect GTP hydrolysis, or
induce dimerization of GDP-bound MFN2IM (Supplementary
Fig. 5f, g), suggesting that the MFN2IM-GDP dimer in the crystal
structure is not dependent on citrate.
The area of the MFN2IM-GDP dimeric interface (G interface)
excluding citrate ions is 1065 Å2, which exceeds the 984 Å2
interface of the MFN1IM-GDP dimer of the posttransition state32.
By comparing the catalytic sites between our MFN2IM-GDP
structure and MFN1IM in the transition state (MFN1IM-
GDPBeF3 )33, we found that their switch I regions are very
similar in overall conformations, as are the positions of the
catalytic threonine (Fig. 3b). When the G domains are super-
imposed, the HD1 of MFN2IM takes an open orientation similar
to the MFN1IM-GDP dimer (Supplementary Fig. 6a). On the G
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Table 1 Crystallographic data collection and refinement
State MFN2IM MFN2IM MFN2IM(T111D)
apo GDP apo
Data collection
Space group P1211 P41212 P1211
Cell dimensions
a, b, c (Å) 84.5,
128.4, 91.3
49.6,
49.6, 388.1
44.4, 126.6, 78
α, β, γ (°) 90, 106.3, 90 90 90, 102.5, 90
Wavelength (Å) 0.97915 0.977760 0.97914
Resolution (Å) 48.7–2.8
(2.98–2.81)
49.6–2.0
(2.12–2.00)
126.6–2.1
(2.14–2.09)
Rsyma 0.106
(0.490)
0.058
(0.475)
0.070 (0.573)
I/σ(I) 10.42 (3.05) 18.31 (3.22) 10.6 (2.2)
Completeness (%) 98.0 (94.5) 99.3 (98.2) 98.8 (99.5)
Redundancy 3.3 (3.3) 6.2 (5.9) 4.4 (4.3)
Refinement
Resolution (Å) 36.3–2.8 48.1–2.0 31.6–2.1
No. reflections 44910 34449 50316
Rwork/Rfree 0.207/0.283 0.176/0.212 0.176/0.229
No. atoms
Protein 13347 3424 6824
Ligand/ion 7 65 11
Water 132 171 268
B-factors
Protein 52.3 43.9 45.5
Ligand/ion 71.2 51.0 61.2
Water 39.6 46.2 48.9
R.m.s. deviations
Bond lengths (Å) 0.009 0.007 0.008
Bond angles (°) 1.184 0.903 0.943
aNumbers in parentheses represent values from the highest resolution shell
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interface of MFN2IM, the trans interactions include (i) the central
dual salt bridges between Glu230 and Arg259; (ii) a hydrophobic
cluster involving Ile126 on switch I and Trp260/Val273, and (iii)
other hydrogen bonds and salt bridges (Fig. 3c). These contacts
(e.g., the hydrophobic cluster) are more consistent with those
of the MFN1IM-GDPBeF3 dimer. Thus, our MFN2IM-GDP
dimer may represent a posttransition state right after GTP
hydrolysis.
On the other hand, the component monomers of the MFN2IM
dimer stay in different relative positions as compared with the
MFN1IM dimer (Fig. 3d), which leads to some varied trans
residue contacts in the G interface. For example, unlike in
MFN1IM in the transition state, Tyr269 of MFN2IM only
interacts with Asn161, but not with His168 (Fig. 3d and
Supplementary Fig. 6b). More importantly, Glu266 forms an
MFN2-specific trans salt bridge to Lys307, whose side chain is in
parallel with the guanine group of the nucleotide (Fig. 3e). This
association, together with the central salt bridge and η1G, tightly
enwraps the nucleotide. For MFN1IM, corresponding residues are
apparently relocated, resulting in a free space next to the
nucleotide (Fig. 3f, g).
Tight G interface ensures high tethering efficiency to MFN2.
The trans interactions were verified by single-point mutagenesis
analysis. RALS analysis indicated that, except for
MFN2IM(V273D) which completely abolished dimerization in the
transition state, most of these mutants only led to partial or
negligible destabilization of MFN2IM dimer (Fig. 4a, Supple-
mentary Fig. 6c). The resistance of the G interface to point
mutations is in agreement with the stability of the MFN2IM
dimer. Analytical ultracentrifugation (AUC) assay revealed that
the MFN2IM dimer indeed has a much stronger trans association
than MFN1IM in the presence of GDPBeF3 , reflected by an
increased dimer fraction at an equal protein concentration
(Fig. 4b). We then performed a spectroscopic tethering assay.
MFN2IM or MFN1IM were fused with MFN2 or MFN1 trans-
membrane domain (MFN2IM-TM or MFN1IM-TM), and recon-
stituted to liposomes (Supplementary Fig. 6d, e). The tethering of
the proteoliposomes caused solution turbidity, which was mon-
itored by measuring the light absorbance at a wavelength of 405
nm. Once GTP was added, MFN2IM-TM tethered liposomes in a
significantly higher efficiency as compared with MFN1IM-TM
(Fig. 4c).
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To examine how G domain dimerization affects GTP turnover
rate, we designed a nucleotide exchange assay by instantaneously
mixing preincubated MFN1/2IM-GDP (monomeric) or MFN1/
2IM-GDPBeF3 (dimeric) with fluorescently-labeled GTP (mant-
GTP) using stopped-flow. The initial slope of the fluorescent
increase indicates the efficiency of mant-GTP reload. Although
MFN2IM bound more mant-GTP over time due to a higher
affinity to GTP as compared with MFN1IM, the mant-GTP reload
to MFN2IM was much slower. G domain dimerization greatly
reduced the mant-GTP reload rate of both MFN2IM and MFN1IM
(Fig. 4d). MFN2IM(T129I) and MFNIIM(I108T) showed pro-
moted and reduced mant-GTP reload rates compared with wild-
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type proteins in GDPBeF3 condition, respectively (Fig. 4e),
suggesting that the Thr/Ile difference also plays an important role
in G domain dimerization. In consistent with this, swapping
MFN1-Ile108/MFN2-Thr129 elevated tethering activity for
MFN1IM and drastically reduced it for MFN2IM (Fig. 4c). A
structural explanation is that, compared with MFN1-Ile108,
MFN2-Thr129 is more favored in the polar G interface for
maintaining dimerization (Fig. 4f). Whether interrupting dimer-
ization or not, the G interface mutants of MFN2IM had
comparable GTP turnover with wild type (Supplementary Fig. 6f).
Altogether, the tight trans interaction within MFN2 dimer is
likely to confine the conformational dynamics of switch I and
prevent the reload of GTP, which ultimately accounts for the low
GTP turnover rate (Fig. 4g). On the other hand, living cells seem
quite sensitive to mutations in the G interface, as mutants I126D,
N161A, and K307A were highly defective in mitochondrial
elongation assays, although some residual activity remained
(Fig. 4h).
MFN2 interacts with MFN1 via the G interface. Surface con-
servation analysis using 12 mitofusin sequences from zebra fish to
human revealed that the G interface is a highly conserved area in
mitofusins (Fig. 5a). Given the fact that MFN1 and MFN2 share
many key residues for G domain dimerization, we postulated that
the G interface is involved in the formation of mitofusin hetero-
complexes. To explore this idea, we performed pull-down assays
in different nucleotide-loading conditions. MFN2IM substantially
co-eluted with glutathione S-transferase (GST)-tagged MFN1IM
in the presence of GTP or GDPBeF3 . GDP also led to weak
association between the two proteins, but this hetero-association
was not observed in apo or GTPγS-bound conditions (Fig. 5b).
The G interface mutants MFN2IM(E230A) and MFN2IM(R259A)
failed to interact with their MFN1IM counterparts (Fig. 5c). When
maltose-binding protein (MBP)-fused MFN1IM and His6-tagged
MFN2IM were mixed together with GDPBeF3 , the
MFN1IM–MFN2IM heterodimer was efficiently formed and could
be stably purified (Fig. 5d, e). The hydrolysis-deficient
MFN2IM(T130A) was able to stimulate the GTP turnover of
MFN1IM in a similar manner to MFN1IM self-stimulation32, and
the introduction of two G interface mutations significantly wea-
kened this effect (Fig. 5f). Liposomes that carry MFN1IM fused
with a transmembrane domain of Sac1 (MFN1IM-TMSac1) were
able to tether MFN2IM-TMSac1-associated liposomes in the pre-
sence of GTP or GDPBeF3 , and the tethering was disrupted by
the G interface mutants (Fig. 5g).
MFN1IM was shown to have conformational dynamics coupled
to the GTP turnover cycle33. In the transition state, the MFN1IM
dimer bends via the hinge 2, and the two HD1s move close to
each other. This domain rearrangement can be monitored by
FRET changes between labeled residues at appropriate positions.
To understand whether MFN2IM also has this feature, we
introduced Cy3/Cy5 labels to MFN2IM at the distal end of HD1
(Supplementary Fig. 7a–d), and traced the ensemble FRET in
different nucleotide-loading states. Addition of GTP, GDPBeF3 ,
or GDP induced immediate FRET increase, whereas G interface
mutants had no FRET change in all conditions (Fig. 5h).
Similarly, mixture of differentially labeled MFN1IM and MFN2IM
also exhibited FRET increase when GTP or GDPBeF3 was
supplied, and this FRET increase was apparently dependent on
the G interface (Fig. 5i). These results confirmed that MFN2
confers domain rearrangement, and can associate with MFN1 via
the G interface in a nucleotide-dependent manner (Fig. 5j).
Structural and biochemical investigations of CMT2A muta-
tions. Mutations in the Mfn2 gene are main cause of CMT2A.
Most of these mutations result in single amino substitutions that
are mainly distributed in the G domain and HD1. Although some
CMT2A-related MFN2 mutations have been studied based on
MFN1 structures31,33, more accurate conclusions require com-
prehensive analysis using a bona fide human MFN2 structure as
the two mitofusins display substantial difference in the organi-
zation of G interface and GTPase activity. We plotted reported
CMT2A mutations on the MFN2IM structural model. The
majority of them are on the surface of the protein (Fig. 6a). For
example, the frequently mutated residues Arg104, Thr105,
Gln276, and Arg280 are distributed around the G interface
(Supplementary Fig. 8a). Arg94 is neighboring the hinge 2 linking
G domain and HD1 (Supplementary Fig. 8b). Arg364 and Trp740
are on the surface of HD1 (Supplementary Fig. 8c). These surface-
exposed disease-related residues are not involved in the intra-
molecular interactions, except that Arg104 forms a salt bridge
with Asp204 in the GDP-bound state (Supplementary Fig. 8d).
Overall, most of these mutations are not likely to severely disrupt
folding of MFN2, as was corroborated by circular dichroism (CD)
analysis (Supplementary Fig. 8e).
To explore the biochemical influence of these mutations, we
tested 20 MFN2IM constructs, each with a CMT2A-related
mutation distributed in various regions of MFN2. Interestingly,
over half of the mutants showed elevated GTPase activity
compared with wild type, suggesting that slow GTP turnover is
a crucial attribute for MFN2’s physiological function. Of these
mutants, T105M and N131S are either on the P-loop or Switch I,
and thus their direct influence on GTP turnover is intuitive. In
contrast, L248V and P251L on the G domain, R94W and R94Q
on the hinge 2, as well as R364P and R364W on HD1 are all
distant from the catalytic site but strongly promoted GTP
turnover (Fig. 6b). By referring to the GDPBeF3 -bound
structure of MFN1IM33, we noted that Leu248, Pro251, and
Arg364 are likely involved in the putative interface between the G
domain and the reoriented HD1 (Fig. 6c, d). For example, Arg343
Fig. 4 Characterization of MFN2IM dimeric interface. a Dimerization property of the G interface mutants in the presence of GDPBeF3 was assayed by
analytical gel filtration coupled to RALS. Calculated molecular masses at the absorption peaks of 280 nm are plotted in red. mAU milli-absorption units.
b AUC results of MFN2IM and MFN1IM (theoretical molecular mass 52.6 and 50.9 kDa, respectively) in the presence of GDPBeF3 . The estimated
molecular masses determined by sedimentation velocity are given in kilodaltons (kDa) above the peaks. c Liposome tethering assay for wild-type MFN2IM-
TM/MFN1IM-TM and mutants. A representative plot from three independent experiments is shown. d Dimerization via the G interface slows down the
nucleotide exchange of MFN2IM and MFN1IM. The initial part of each fluorescence trace was magnified. e Effect of MFN2IM(T129I) and MFN1IM(I108T) on
the nucleotide exchange efficiency in the dimeric state. The initial part of each fluorescence trace was magnified and fitted to exponential function as
shown in a white curve. f Surroundings of MFN2-Thr129 and MFN1-Ile108 in the dimerization form. gModel for comparison between MFN2 and MFN1 in G
domain dimerization. Note the tighter G interface of MFN2 and its sustained dimerization in the GDP-bound state. Pi denotes phosphate group.
h Mitochondrial elongation assay with quantification for wild-type MFN2 and G interface mutants. Representative images are shown. Mfn1/2-null MEFs
were transduced with retrovirus expressing 16× Myc-tagged WT Mfn2 or G interface mutants. Actin was used as a loading control. A lysate from WT
MEFs is shown for comparison. For each construct, 100 cells were scored in biological triplicate. Error bars indicate s.e.m. Scale bars, 10 μm. Source data
are provided as a Source Data file
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Fig. 5MFN2 interacts with MFN1 via G domain. a Surface conservation analysis reveals that the G interface is a highly conserved area in mitofusins. b Pull-
down assays showing the interaction between MFN2IM and GST-tagged MFN1IM in different nucleotide-loading conditions. c Pull-down assays showing
that the interaction between MFN2IM and MFN1IM is dependent on the G interface. d Native PAGE result showing the association between MFN2IM and
MBP-fused MFN1IM. e SDS-PAGE showing the purified MFN2IM/MBP-MFN1IM hetero-complex. f MFN2IM stimulates GTP turnover of MFN1IM. Overall,
0.25 μM MFN1IM and 2.5 μM MFN1IM MFN2IM mutants were used. g Liposome tethering assay for wild-type MFN2IM/MFN1IM and G interface mutants.
Representative images from five independent experiments are shown. Scale bar, 50 μm. h FRET experiment showing the G domain dimerization-dependent
conformational change of MFN2IM in different nucleotide-loading conditions. The time point for the addition of corresponding nucleotides is indicated by an
arrow for each panel. nt denotes nucleotide. i FRET experiment showing the conformational change of MFN2IM and MFN1IM upon association via the G
domains in GTP- and GDPBeF3 loading conditions. j A model for the trans association between MFN2IM and MFN1IM. Source data are provided as a
Source Data file
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12912-0
8 NATURE COMMUNICATIONS |         (2019) 10:4914 | https://doi.org/10.1038/s41467-019-12912-0 | www.nature.com/naturecommunications
in MFN1, which is equivalent to MFN2-Arg364, forms a
hydrogen bond with Asn224. Mutagenesis of these residues
would disrupt this interface, thereby intervening the relative
movement of G domain and HD1. R94W and R94Q are also
expected to disturb the conformational dynamics of MFN2. These
six mutants did not significantly perturb dimerization via the G
interface (Fig. 6e), while some of their counterparts on MFN1
do33. This highlights a direct mechanistic coupling between the
GTPase activity and domain rearrangement for MFN2 regardless
of nucleotide-dependent dimerization, and may be relevant to a
recent observation that a R364W-like mutation causes excessive
mitochondrial fusion in a Drosophila model39.
While some CMT2A-related mutations occurring at the G
interface (R104W, T105M, G127V) prevent the dimer formation
in the transition state of GTP hydrolysis, other mutants could still
dimerize (Supplementary Fig. 8f). To further test whether they are
able to associate with wild-type mitofusins via G domains, we
individually mixed the mutants with either MBP-fused MFN2IM
or MFN1IM in the presence of GDP•BeF3−. Native PAGE analysis
indicated that except those on the G interface, the majority of the
CMT2A-related mutants efficiently heterodimerized with wild-
type MFN2IM or MFN1IM (Fig. 7a). The R94W mutant, as an
example, even formed no homodimers but only heterodimers
with wild-type MFN2 or MFN1, which coincides with a previous
co-immunoprecipitation study in human U2OS cells40. This
implicates that corresponding mutations may have a dominant
negative effect on the occurrence of CMT2A. The structural and
biochemical information of available CMT2A-related mutations
is summarized in Supplementary Table 1.
Discussion
MFN2 and its homologs play pivotal roles in mitochondrial
homeostasis and cell metabolism from yeast to human. Our study
reveals the structural and biochemical features of this key mole-
cule that underlie its divergent functions. MFN2 possesses most
of the traits of the dynamin superfamily such as domain orga-
nization and G domain-mediated dimerization. However, unlike
almost all other members (including human MFN1) with
dimerization-stimulated GTPase activity that entails frequent
attaching–detaching cycles of the G domains coupled with mul-
tiple rounds of GTP hydrolysis, MFN2 has a hydrolyze-but-not-
dissociate feature. Keeping basal (low) GTP turnover seems
crucial for the cellular function of MFN2, as many GTPase
b
P251L
0
50
13.5 15.5 17.5
0
50
100
M
as
s 
(k
D
a)
A
28
0 
(m
A
u)
Retention volume (ml)
L248V
0
50
100
13.5 15.5 17.5
0
50
100
A
28
0 
(m
A
u)
M
as
s 
(k
D
a)
Retention volume (ml)
150
200
R94Q
13.5 15.5 17.5
0
50
100
M
as
s 
(k
D
a)
0
50
100
150
200
A
28
0 
(m
A
u)
Retention volume (ml)
R364P
0
50
100
13.5 15.5 17.5
0
50
100
A
28
0 
(m
A
u)
M
as
s 
(k
D
a)
Retention volume (ml)
150
200
R94W
13.5 15.5 17.5
0
50
100
M
as
s 
(k
D
a)
0
50
100
A
28
0 
(m
A
u)
 
Retention volume (ml)
R364W
0
50
13.5 15.5 17.5
0
50
100
M
as
s 
(k
D
a)
A
28
0 
(m
A
u)
Retention volume (ml)
100
150
200
d
c e
L248
P251
R364
R364
G interface
GD-HD1
GTP binding
Hinge 2
P251 L248
S245
R364
V91
I88
P230
L227
N224
R343
V70
I66
I67
MFN1IM
MFN2IM
k c
at
 (
m
in
–1
)
W
T
G1
27
V
R1
04
W
P2
51
R
C1
32
T
V2
73
G
Q2
76
H
R2
80
H
L2
18
P
H1
65
R
N1
31
S
P2
51
L
L2
48
V
T1
05
M
R9
4W
R9
4Q
M
37
6L
W
74
0S
L7
6P
R3
64
P
R3
64
W
0
0.5
1
1.5
2
2.5
Hinge 2 HD1G domain
V69
L724L76
M376
A738
W740
R364
H361
T362
L92
R94
T356
S249
L248
R250
L218
F216
S350
I213
L146
C132
N131
E347
N252D210
D214
P123
T105
R104
R259
I203
T206
H277
L233
Q276
S263
C390
a
S156
H165
R280
T236
G298
F284
E288
V244 P251
H750
K357
F223
S378
A716
L710
R707
R400
L745
E744
M747
L248P251 R364
R94
T105
N131
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activity-promoting mutants are associated with CMT2A onset. Of
these mutants, T105M and P251L have been previously shown to
lack fusogenic activity41. The more stable G domain dimerization
and potent tethering activity, as compared with human MFN1 in
our experiment, imply that MFN2 may act as a GTP-regulated
molecular sticker for mitochondria. GTP-loaded MFN2 mole-
cules may be able to establish enduring trans anchoring of jux-
taposing mitochondria throughout hydrolysis cycle. Although
MFN2 has been previously reported to bear weaker tethering
activity than MFN111, the isolated MFN2 used in the tethering
experiment may already have been loaded with host GDP. Thus,
it is tempting to speculate that MFN2 molecules serve as initial
mitochondrial anchors in the beginning of the fusion process.
The free and vigorous relative movement between HD1 and HD2
via hinge 1, as found also in dynamin-like MxA and bacterial
DLPs42–44, may draw the tethered mitochondrial segments
together. This proposed mechanism is economic in GTP con-
sumption, thereby ensuring that mitochondrial tethering can
happen at low local MFN2 or GTP concentrations. Given the
tight G interface of MFN2, it is possible that external partners,
such as the Smad2-RIN1 complex that are reported to promote
GTP turnover of MFN245, help with G domain dissociation after
GTP hydrolysis. Other cellular factors may also participate in the
regulation of MFN2: the potential of binding Ca2+ and citrate
found in the crystal structure implies a possibility of physiological
relevance between MFN2 and these molecules. It has been
recently reported that Ca2+ affects mitochondrial fusion by
inhibiting MFN1 assembly46, and citrate is known to be
transported to cytoplasm from Krebs cycle and modulate acetyl-
CoA carboxylase for fatty acid metabolism47. Can they somehow
influence OMM fusion through direct interaction with MFN2 in
living cells? It may be worthwhile to explore these ideas.
A following question is whether the tethering efficiency of
MFN2 translates to high fusogenic activity. On one hand, tight
dimerization and resulting low GTP turnover rate of MFN2 may
not favor mitochondrial fusion, as the fusion event requires
continuous GTP hydrolysis cycles. Firmly trans-associated MFN2
molecules stacking between two segments of mitochondrial outer
membrane may even prevent their contact. On the other hand, if
these trans-associated MFN2 molecules are organized in so-called
docking ring complexes as reported earlier in an in vitro assay for
yeast Fzo148, mitochondrial fusion may be promoted. We used
internally truncated MFN1/2 variants in liposome tethering
assays, and they lack the HD2 region which is indispensible for
fusion. Although previous studies showed that MFN1/2 (or Fzo1)
are able to fuse mitochondria in vitro by using mitochondria
isolated from mouse embryonic fibroblasts (MEFs)49 or yeast48,
one cannot exclude the possibility that these mitochondria carry
other adapters (specific lipids or proteins) that are essential for
fusion. To understand whether MFN2 (or MFN1) on its own can
efficiently catalyze mitochondrial outer membrane fusion, an
in vitro fusion assay using full-length mitofusin and clean mito-
chondria (or liposomes) will be needed.
The difference between human MFN1 and MFN2 in GTP
turnover efficiency largely derives from the Ile108/Thr129 variance,
which can lead to difference in the flexibility of switch I and also in
a
MFN2IM monomer
MBP-MFN1IM monomer
MFN2IM homodimer
MFN2IM/MBP-MFN1IM heterodimer
MBP-MFN1IM homodimer
+  +  ++  +  +   ++ +  +   ++  +  +   ++  +  +   ++  +  +   ++  +  
+  ++  +  +  ++  +   + +  +   ++  +  +   ++  +  +   ++  +  +  +  ++  –
–– ––
– –
–
–
–– WTWT WT WT G1
27
V
R
10
4W
P2
51
R
C
13
2T
V2
73
G
Q
27
6H
R
28
0H
L2
18
P
H
16
5R
P2
51
L
L2
48
V
T1
05
M
R
94
W
R
94
Q
M
37
6L
W
74
0S
R
36
4P
R
36
4W
N
13
1S
– –WT WT WT
MBP-MFN1IM
MFN2IM
GDP•BeF3
+  +  ++  +  +   ++  +  +   ++  +  +   ++  +  +   ++  +  +   ++  +  
+  ++  +  +  ++  +   + +  +   ++  +  +   ++  +  +   ++  +  +  +  ++  –
–– ––
– –
–
–
–– WTWT WT WT G1
27
V
R
10
4W
P2
51
R
C
13
2T
V2
73
G
Q
27
6H
R
28
0H
L2
18
P
H
16
5R
P2
51
L
L2
48
V
T1
05
M
R
94
W
R
94
Q
M
37
6L
W
74
0S
R
36
4P
R
36
4W
N
13
1S
– –
MFN2IM monomer
MBP-MFN2IM monomer
MFN2IM homodimer
MFN2IM/MBP-MFN2IM heterodimer
MBP-MFN2IM homodimer
WT WT WT
MBP-MFN2IM
MFN2IM
GDP•BeF3–
–
CMT2A possibility I
Outer membrane
Mitochondria
CMT2A possibility II
Outer membrane
Mitochondria
b
Outer membrane
Normal
Mitochondria
MFN2
MFN1
MFN2 with dimerization-defective CMT2A mutation
MFN2 with dimerization-compatible CMT2A mutation
Abolished dimerization
Dimerization but possibly weakened fusion
Fig. 7 Interaction between CMT2A-related mutants and wild-type MFN1/2IM. a G domain-mediated association of CMT2A-related MFN2IM mutants with
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the stability of G interface. By careful sequence screening, we found
that this single amino acid variance of MFN1/2 only exists in pri-
mates (Supplementary Fig. 4b). In this context, the particularly high
GTPase activity of human MFN1, as compared with other mito-
fusins, suggests that primates may have special needs for mito-
chondrial fusion. In line with these ideas, MFN1 in nonprimate
mammals is likely to share more functional redundancy with MFN2
as they do not display the Ile/Thr variance in switch I. As currently
there is no MFN1 knockout data for primates, the question why
MFN1 mutations are not found to be clearly related with human
diseases, say CMT2A, may have two distinct answers: (i) primate
MFN2 is unable to compensate for defective MFN1, and detri-
mental mutations in MFN1 cause death in early embryonic devel-
opment; (ii) primate MFN2 can efficiently substitute defective
MFN1 but not vice versa, therefore only defects in MFN2 lead to
disease. Given this functional complexity, the physiological role of
MFN1 in humans needs to be dissected in more detail, and proper
animal models are required.
The heterodimerization between human MFN2 and MFN1
found in our study is likely to occur in trans and compete with
homotypic MFN1/MFN2 associations during mitochondrial
fusion as the two types of interactions are both mediated by the G
interface. According to the native PAGE results, the tendency of
MFN1–MFN2 heterodimerization in vitro is even stronger than
that of homodimerization (Figs. 5d, 7a). If this is true also for
mouse mitofusins, it may partly explain the previous observation
that heterotypic MFN1/MFN2 trans complexes show greater
fusogenic efficacy in MEFs as compared with homotypic MFN1
or MFN2 complexes49. It is important to investigate the particular
physiological role of this heterodimerization in OMM fusion and
ER–mitochondria tethering in vivo in the future, and our results
contribute to the development of more efficacious methodologies
for this purpose.
Based on our CD spectroscopy experiments, the majority of
reported CMT2A-related missense mutations do not seem highly
detrimental to protein folding. Some of these mutants may even
preserve a certain level of functionality in OMM fusion. These
mutations can be mapped to at least four functional zones of the
molecule, including (I) the nucleotide-binding site (the P-loop,
Switch I/II and G4 motif), (II) G interface, (III) hinge 2, and (IV)
G domain-HD1 interface (Fig. 6d, Supplementary Table 2). The
consequence of these mutations in these zones can therefore be
predicted from the biochemical feature of MFN2. For example,
R104W of the nucleotide-binding site, R94W of hinge 2 and
R364P of the G domain-HD1 interface all cause severe CMT2A
phenotype, whereas the dominant L745P and Q276R mutations,
which are beyond the above four functional zones, only lead to
mild or moderate disease conditions50. It is also possible that,
mutations of residues beyond these zones but involved in critical
interaction with other partners of MFN2, also results in severe
CMT2A phenotype.
Different mechanisms for MFN2-related CMT2A occurrence
are also expected on the intermolecular level. The dimerization-
deficient T105M mutant is highly defective in promoting mito-
chondrial fusion41, but it is less likely to affect the functionality of
wild-type MFN1 and MFN2, at least in terms of G domain
association. Consequently, the development of the CMT2A
phenotype in T105M patients are likely due to reduced cellular
level of normal MFN2. This mechanism possibly also applies to
MFN2 mutations that lead to unfolded or truncated proteins. On
the other hand, those mutants that are still able to dimerize and
retain residual fusogenic activity, as compared with MFN2
(T105M), tend to have a dominant negative effect through
hijacking normal MFN1 and allelic MFN2, which eventually
results in a pervasively weakened MFN2 and MFN1 activity
(Fig. 7b). In this case, the level of retained fusogenic activity of the
mutant is a key determinant for the onset of the disease. Alto-
gether, this information will be valuable for the diagnosis and
prognosis of CMT2A cases, and for the development of perso-
nalized treatments targeting particular MFN2 mutations.
Methods
Protein expression and purification. The engineered MFN2 construct (MFN2IM)
was cloned into a modified pET-28 vector. Details of this construct are illustrated
in Fig. 1a. All mutants were generated by site-directed mutagenesis. Primer
sequences for amplification and cloning here are provided in Supplementary
Table 2 (primers 1–4). Recombinant MFN2IM proteins containing an N-terminal
His6-tag followed by a cleavage site for PreScission protease (PSP) were expressed
in E. coli Rosetta (DE3) cells (Invitrogen). Transformed bacteria were cultured at
37 °C before induced with 0.1 mM isopropyl-1-thio-β-d-galactopyranoside (IPTG)
at an OD600 nm of 0.6, and grown for 20–24 h at 17–18 °C in Terrific Broth
medium. Initially, human MFN2IM was purified following our previous protocol
for MFN1IM32, which was used for obtaining GDP-bound MFN2IM crystals. To
remove host-derived nucleotides bound to MFN2IM, cells were lysed in 50 mM
HEPES, pH 7.5, 1 M NaCl, 30 mM imidazole, 2.5 mM β-mercaptoethanol (β-ME),
1 μM DNase I, and 1 mM phenylmethanesulfonylfluoride (PMSF) using a cell
disruptor (JNBIO) and subjected to centrifugation at 40,000 g for 50 min. The
supernatant was filtered and applied to an Ni-NTA (first Ni-NTA) column (GE
Healthcare) equilibrated with buffer A containing 20 mM HEPES, pH 7.5, 1 M
NaCl, 30 mM imidazole, and 2.5 mM β-ME. After washed with buffer A, protein
was eluted with 20 mM HEPES, pH 7.5, 1 M NaCl, 300 mM imidazole, and 2.5 mM
β-ME. Eluted proteins were incubated with 20 μg glutathione S-transferase (GST)-
fused PSP to remove the His6-tag and dialyzed overnight against buffer B con-
taining 20 mM HEPES, pH 7.5, 800 mM NaCl, 2.5 mM β-ME. After dialysis, PSP
was removed by a GST column. The protein was reapplied to a second Ni-NTA
column equilibrated with buffer B and eluted with buffer A, and further purified by
gel filtration chromatography (Superdex 200 16/60 column, GE Healthcare) in
buffer C containing 20 mM HEPES, pH 7.5, 150 mM KCl, 5 mM MgCl2, and 1 mM
dithiothreitol (DTT). For nucleotide-free MFN2IM used in crystallization experi-
ments, KCl was substituted by NaCl in buffer C during gel filtration.
His6-tagged MFN1IM and mutants were purified as previously described32. Cells
expressing MFN1IM or mutants were lysed in 50 mM HEPES, pH 7.5, 400 mM
NaCl, 5 mM MgCl2, 30 mM imidazole, 1 μM DNase I, 1 mM PMSF, and 2.5 mM β-
ME and subjected to centrifugation at 40,000 g for 1 h. The supernatant was filtered
and applied to a Ni-NTA (first Ni-NTA) column (GE Healthcare) equilibrated with
binding buffer D containing 20 mM HEPES, pH 7.5, 400 mM NaCl, 5 mM MgCl2,
30 mM imidazole, and 2.5 mM β-ME. After washed with binding buffer D, proteins
were eluted with elution buffer containing 20 mM HEPES, pH 7.5, 400 mM NaCl,
5 mM MgCl2, 300 mM imidazole, and 2.5 mM β-ME. Eluted proteins were
incubated with 20 μg GST-fused PSP to remove the His6-tag and dialyzed overnight
against binding buffer E containing 20 mM HEPES, pH 7.5, 400 mM NaCl, 5 mM
MgCl2, and 2.5 mM β-ME. After dialysis, PSP was removed using a GST column.
The protein was reapplied to a second Ni-NTA column equilibrated with binding
buffer E. Binding buffer D was used to elute the proteins which were subsequently
loaded onto a Superdex 200 16/60 column (GE Healthcare) equilibrated with gel
filtration buffer C. Cell lysis and protein purification were both performed at 4 °C.
E. coli cells expressing GST- and MBP-fused MFN1IM (recombinant in pGEX-
6p-1 vector or a modified MBP vector, a gift from Professor Tengchuan Jin), as well
as corresponding mutants, were cultured and lysed in similar protocols as His6-
tagged MFN1IM construct, but the lysis buffer contains no imidazole. In the
affinity chromatography experiments, elution buffer contains either 15 mM
reduced glutathione (GSH) for GST-fused MFN1IM, or 10 mM maltose for MBP-
fused MFN1IM. The protein was purified by gel filtration chromatography in buffer
C. All cell lysis and protein purification performances were carried out at 4 °C.
Primer sequences for amplification and cloning here are provided in
Supplementary Table 2 (primers 27 and 32 for pGEX-6p-1 vector; primers 5–8 for
MBP vector).
For transmembrane domain (TM)-fused MFN1IM or MFN2IM used in
spectroscopic tethering assay. The original residues 365–694 of MFN1 were
replaced with the TM of codon-optimized MFN1 (residues 596–628) flanked by
amino acid sequences SGSGSGGS (N-terminal) and GSGS (C-terminal) using
overlap PCR. The original residues 401–705 of MFN2 were replaced with the TM
of MFN2 (residues 615–647) flanked by SAASA (N-terminal) and ASAA (C-
terminal). The fragments were individually cloned into the pGEX-6p-3 vector.
Primer sequences for amplification and cloning here are provided in
Supplementary Table 2 (primers 9–20). All point mutations were generated by site-
directed mutagenesis. MFN1IM-TM, MFN2IM-TM and corresponding mutants
were expressed and purified as previously described33. Plasmids expressing
MFN1IM-TM or MFN2IM-TM were transformed into E. coli BL21 (DE3). Cells
were grown to an OD600 nm of 0.8, induced with 0.3 mM IPTG for 24 h at 16 °C,
and harvested by centrifugation. The pellets were resuspended in buffer F
containing 25 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, and
2 mM β-ME. Membranes were then pelleted by centrifugation at 110,000 g for 1 h,
and dissolved by 1% Fos-choline-12 (Anatrace) in buffer F, and insoluble
components were cleared by centrifugation. The recombinant protein was isolated
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by glutathione Sepharose (GE Healthcare), washed twice with buffer F containing
0.1% Triton X-100 (Anatrace), and the GST-tag was cleaved before reconstitution.
For constructs used in visual tethering assay, the TM of Sac1 (residues 523–580)
was inserted between α3H and α4H of MFN1IM (MFN1IM-TMSac1) or MFN2IM
(MFN2IM-TMSac1) by overlapping PCR, and the fragments were individually
cloned into pGEX-6p-1 vector. Primer sequences for amplification and cloning
here are provided in Supplementary Table 2 (primers 21–32). MFN1IM-TMSac1,
MFN2IM-TMSac1 and corresponding mutants were expressed and purified as
previously described51. Proteins were expressed in E. coli Rosetta (DE3) cells for
16 h at 17–18 °C. Collected cells expressing MFN1/2IM-TMSac1 or its mutants were
lysed in 50 mM HEPES, pH 7.5, 150 mM NaCl, 30 mM imidazole, 10% glycerol, 2%
Triton X-100, 1 µM DNase I, 1 mM PMSF, and 2.5 mM β-ME and centrifugated at
40,000 g for 30 min. After incubation at 4 °C for 1 h, the supernatant was subjected
to further centrifugation at 40,000 g before filtered and applied to a GST column
(GE healthcare) which is equilibrated with binding buffer G containing 50 mM
HEPES, pH 7.5, 150 mM NaCl, 30 mM imidazole, 10% glycerol, 0.1% Triton X-
100, and 2.5 mM β-ME. Target proteins were eluted with buffer G supplied with 15
mM GSH. Target proteins with GST-tags removed were reapplied to a GST column
after dialysis using buffer G. Eluted target proteins were loaded onto a Superdex
200 16/60 column equilibrated with 20 mM HEPES, pH 7.5, 150 mM NaCl, 5%
glycerol, 0.1% Triton X-100 and 1 mM DTT and collected. For MFN2IM-TMSac1 or
its mutants, 1 M NaCl instead of 150 mM NaCl was used in buffer G.
Protein crystallization. MFN2IM constructs were crystallized via hanging drop
vapor diffusion by mixing equal volumes of protein (~20 mgml−1) and reservoir
solution. Crystals of nucleotide-free MFN2IM grew from 0.19 M calcium chloride,
95 mM HEPES, pH 7.5, 26.6% PEG400, 5% glycerol at 4 °C. MFN2IM(T111D) was
crystallized in 0.16M calcium acetate, 0.08M sodium cacodylate pH 6.5, 14.4%
PEG 8000, 20% glycerol at 18 °C. Crystals of GDP-bound MFN2IM were grown
from 0.2M lithium citrate tribasic tetrahydrate, and 35% glycerol ethoxylate at
18 °C using MFN2IM purified with previous protocol for MFN1IM32.
Structure determination. X-ray diffraction datasets were collected at beamlines
BL17U1 and BL19U1 of Shanghai Radiation Facility (SSRF)52 and processed with
the XDS suite53. Structures of MFN2IM were solved by molecular replacement
using MOLREP54 with truncated MFN1IM as the search model. Models were built
with COOT55 and refined with Refmac56 and Phenix57. Structural validation was
carried out using MolProbity58. Structural illustrations were prepared using the
PyMOL Molecular Graphic Systems (version 0.99, Schrödinger LLC; http://www.
pymol.org/). The Ramachandran statistics determined by PROCHECK59 are as
follows: 97.7% in favored region, 2.3% allowed, 0 outlier for apo MFN2IM; 98.3%
favored, 1.5% allowed, 0.2% outlier for MFN2IM(T111D) and 98.6% favored, 1.4%
allowed, 0 outlier for GDP-bound MFN2IM.
Nucleotide-binding assay. The equilibrium dissociation constants for nucleotide-
free MFN2IM, MFN1IM and indicated mutants to guanine nucleotides were
determined by ITC at 25 °C using a MicroCal ITC200 (Malvern) in the buffer
containing 20 mM HEPES, pH 7.5, 150 mM KCl, 5 mM MgCl2. A total of 1–2 mM
nucleotides were used to titrate 80 μM protein. Resulting heat changes upon each
injection was integrated and the values were fitted to a standard single-site binding
model using Origin7.
GTP hydrolysis assay. GTP hydrolysis assays were performed at 37 °C as pre-
viously described32 in buffer containing 20 mM HEPES, pH 7.5, 150 mM KCl,
5 mM MgCl2, and 1 mM DTT. Reactions were initiated by the addition of protein
to the final reaction solution. At different time points, reaction aliquots were 20-
fold diluted in buffer C and quickly transferred into liquid nitrogen. Nucleotides in
the samples were separated via a reversed-phase Hypersil ODS-2 C18 column
(250 × 4.6 mm, Thermo), with 10 mM tetrabutylammonium bromide, 100 mM
potassium phosphate, pH 6.5, and 7.5% acetonitrile as running buffer, where
denatured proteins were blocked by a C18 guard column (Thermo). Nucleotides
were detected by absorption at 254 nm and quantified by integration of the cor-
responding peaks. The GTP hydrolysis rates derived from a linear fit to the initial
phase of the reaction (<40% GTP hydrolyzed) were plotted against the protein
concentrations. For measuring stimulated GTP turnover of MFN2IM and MFN1IM,
proteins at concentrations of 0.5, 1, 2, 4, 8, 16, and 32 μM were individually mixed
with 1–2 mM GTP. For measuring stimulated GTP turnover of MFN1IM by
hydrolysis-deficient MFN1IM or MFN2IM constructs, 0.25 μM MFN1IM and 1 mM
GTP were mixed with 2.5 μM MFN2IM(T130A) or MFN2IM(T130A/E230A/
R259A). For other experiments, 32 μM protein and 2 mM GTP were used.
Fast kinetics assay. To determine the GDP off-rate, 10 μM protein was pre-
incubated with 2 μM N-methyl-3′-O-anthranoyl (mant-)GDP (Jena Bioscience) for
2 h before rapidly mixed with 1 mM unlabeled GDP in a buffer containing 20 mM
HEPES, pH 7.5, 150 mM KCl, 5 mM MgCl2 and 1 mM DTT, and the fluorescence
signal (excitation wavelength 355 ± 4 nm) was instantaneously recorded using a
Chirascan spectrometer equipped with an SX20 Stopped-Flow accessory (Applied
Photophysics). Three injections were individually and consecutively carried out,
and the readouts were averaged to yield a time-dependent fluorescence change
diagram. The GDP off-rates were derived from fitting the fluorescence traces with
single exponential function.
For mant-GTP exchange assay, 5 μM proteins were preincubated with 50 μM
GDP or 50 μM GDP•BeF3¯ (50 μM GDP, 50 μM BeSO4, and 500 μM NaF) at room
temperature for 2 h before rapidly mixed with 2 μM mant-GTP in a buffer
containing 20 mM HEPES, pH 7.5, 150 mM KCl, 5 mM MgCl2, and 1 mM DTT.
RALS. A coupled RALS-refractive index detector (Malvern) was connected in line
to an analytical gel filtration column Superdex 200 10/300 to determine absolute
molecular masses of the applied protein samples. 50 μM purified protein was
incubated with or without 500 μM corresponding ligand for 2 h at room tem-
perature before applied to the column equilibrated with 20 mM HEPES, pH 7.5,
150 mM KCl, 5 mM MgCl2, and 1 mM DTT. Data were analyzed with the
OMNISEC software. All experiments were repeated at least twice and the data
showed satisfying consistency.
Mitochondrial elongation assay. To examine the effect of point mutations,
MFN2–Myc variants were expressed in Mfn1/2-null MEFs10 from the pQCXIP
retroviral vector. The cell line is free of mycoplasma and has been authenticated by
genotyping with PCR to confirm deletion of the Mfn1 and Mfn2 genes. Point
mutants in mouse Mfn2 were constructed by overlapping PCR with primers
encoding the point mutation. For I126D, the 5′ region of the Mfn2 cDNA was
amplified with primers 33 and 34, and subcloned as a NotI/MfeI fragment. For
N161A, two overlapping Mfn2 fragments were amplified with primers 35–38
(N161A). The two fragments were combined, reamplified with primers 35 and 38,
and subcloned as an MfeI/PsiI fragment. The same strategy was used to subclone
K307A, except that primers 39 and 40 were used instead of primers 36 and 37. All
primers used here are provided in Supplementary Table 2.
All mutations were confirmed by DNA sequencing. The types and positions of
the residues mutated in this study are all consistent between human and mouse
mitofusins. Retroviral supernatants were produced from 293T cells transfected with
the retroviral vector and the packaging plasmid pCLEco. Mfn1/2-null MEFs stably
expressing mito-DsRed were maintained in Dulbecco’s Modified Eagle’s Medium
supplemented with 10% fetal bovine serum and penicillin/streptomycin at 37 °C
and 5% CO2. After retroviral transduction of Mfn1/2-null MEFs, puromycin
selection was applied for 2 days. Cells were plated onto eight-well chambered slides
for analysis. Western blot analysis with the 9E10 antibody against Myc (DSHB,
AB_2266850) was performed to confirm proper expression of the MFN2 variant.
Mitochondrial morphology was scored by analysis of mito-DsRed as described
previously10. Cells were imaged with a Plan NeoFluar ×63 objective on a Zeiss 410
laser scanning confocal microscope (Carl Zeiss MicroImaging, Inc.).
Analytical ultracentrifugation. Twenty micromoles of MFN1IM and MFN2IM
mixed with 1 mM GDP, 1 mM BeSO4, and 10 mM NaF were applied to AUC in a
buffer containing 20 mM Tris, pH 8.0, 150 mM KCl, and 5 mM MgCl2. Sedi-
mentation velocity experiments were performed with an An-60 Ti rotor at a speed
of 145,000 g in a ProteomeLab XL-I Protein Characterization System (Beckman
Coulter) at 20 °C. All interference data were processed according to a c(s)
distribution model.
Spectroscopic tethering assay. Purified MFN1IM-TM, MFN2IM-TM, and cor-
responding mutants were reconstituted into preformed liposomes (83.5:15:1.5 mol
% POPC/DOPS/Rhodamine-DPPE) as previously described33. Two micromoles of
protein was reconstituted into 2 mM liposome in buffer H (25 mM HEPES, pH 7.4,
150 mM KCl, 10% glycerol), and detergent was removed by Biobeads. Five milli-
moles of MgCl2 was added immediately before measuring the absorbance at
405 nm. Data were collected every 30 s using a Microplate Reader (Tecan). The
absorbance before nucleotide addition was set to zero. To verify reconstitution
efficiency, 30 µl proteoliposomes were mixed with 100 µl of 1.9 M sucrose and
overlaid with 100 µl of 1.25M sucrose and 20 µl buffer H supplied with 1 mM
EDTA and 2 mM β-ME. After centrifugation in a Beckman TLS-55 rotor at
174,000 g for 75 min at 4 °C, 50 µl fractions were collected from the top of the
gradient. Top and bottom fractions were analyzed by SDS-PAGE.
Visual tethering assay. POPC, DOPS, Texas Red DHPE, or Oregon green 488
DHPE (ThermoFisher) were mixed in a molar ratio of 84.5:15:0.5 as previously
described51. Overall, 0.3 μM MFN1IM-Sac1TM or MFN2IM-Sac1TM or corre-
sponding mutants were reconstituted into 0.6 mM prepared liposomes with Texas
Red DHPE or Oregon green 488 DHPE in a buffer containing 20 mM HEPES, pH
7.5, 150 mM NaCl, 5 mM KCl, 5% glycerol, and 2% β-ME. Proteoliposomes labeled
with red and green dyes were 1:1 mixed, 1 mM ligands and 5 mM MgCl2 were
subsequently added. Samples were incubated at 37 °C for 0.5 h before imaged by a
confocal laser scanning microscopy (OLYMPUS FV1000).
Surface conservation plot. Protein sequences of 24 mitofusins were aligned using
Clustal Omega60 (https://www.ebi.ac.uk/Tools/msa/clustalo/). These sequences from
12 vertebrate species included MFN1 and MFN2 from Homo sapiens (UniProt
accession Q8IWA4 and O95140, respectively), Sus scrofa (M3VH65 and F1RF76),
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Bos taurus (F1MPL1 and D7GLD0), Equus caballus (F6VTU8 and F6YL70), Ovis
aries (W5QHQ0 and W5Q8M0), Canis lupus familiaris (F1Q1G1 and E2R3M9),
Oryctolagus cuniculus (G1SEC8 and G1SU75), Felis catus (A0A1D5PYU0 and
M3VU19), Mus musculus (Q811U4 and Q80U63), Gallus gallus (A0A1D5PER5 and
E1BSH7), Xenopus tropicalis (Q28FR9 and F6QKB9), and Danio rerio (Q6PFP9 and
A8WIN6), The alignment result and structure of MFN2IM-GDP complex were
uploaded to the ConSurf online server61 (http://conseq.tau.ac.il) to compute con-
servation scores for the residues. Surface plot of MFN2IM with conservation score-
based coloring was generated using PyMOL Molecular Graphic Systems (version
0.99, Schröinger LLC; http://www.pymol.org/).
Pull-down assay. Twenty micrograms of GST-tagged MFN1IM was incubated with
60 μg MFN2IM with or without 2 mM corresponding ligand for 2 h at 4 °C in a
buffer containing 20 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl2, and 1 mM
DTT. The mixtures were sampled to 100 μg GST beads (GE Healthcare) and then
washed with the same buffer. Proteins retained by the GST beads were eluted by
extra 20 mM GSH before analyzed by SDS-PAGE.
Native PAGE. Blue native PAGE technique was used to check the homo- and hetero-
dimerization of MFN2IM. Ten micromoles of MBP-tagged MFN1IM/MFN2IM was
mixed with 10 μΜ untagged MFN1IM/MFN2IM in the absence or presence of tenfold
concentration of indicated nucleotides for 2 h at room temperature. The samples were
then mixed with 5× loading buffer (1%[w/v] bromophenol blue, 50%[v/v] glycerol)
and subjected to native PAGE analysis at 4 °C. Electrophoresis was performed at
100 V for 20min in 4% stacking gel, and then 160 V for 70min in separating gel. The
gel was stained with Coomasie brilliant blue.
FRET assay. MFN1IM(C156S+ A696C), MFN2IM(C390S+ A706C), and related
mutants were labeled with fivefold concentration of fluorescent dye Cy3 or Cy5
(GE Healthcare) for 60 min at 4 °C in a buffer containing (20 mM HEPES, pH
7.5, 150 mM KCl, 5 mM MgCl2, and 0.5 mM Tris(2-carboxyethyl)phosphine
(TCEP). Free dye was removed by gel filtration chromatography using a
Superdex 200 10/30 column. Cy3 was excited at 537 nm, with peak emission at
570 nm. Cy5 fluorescence emission was detected at 667 nm. Cy3- and Cy5-
labeled proteins (1 μΜ each) were mixed in a buffer containing 20 mM HEPES,
pH 7.5, 150 mM KCl, 5 mM MgCl2, and 2% β-ME as previously described33.
Fluorescence was measured once every 1 min in a flat black 96-well plate for
40 min, then 2 mM indicated nucleotide was added and the measurement con-
tinued for another 60 min. FRET traces were calculated as: FRET= ICy5/(ICy3+
ICy5), where ICy3 and ICy5 are the instantaneous Cy3 and Cy5 fluorescence
intensities, respectively.
Circular dichroism. Proteins were diluted to 0.1 mg ml−1 in ddH2O and applied to
CD measurements using a Chirascan spectrometer (Applied Photophysics) in
quartz cuvettes with path length of 0.5 mm. Spectra were recorded from 180 to
260 nm at a bandwidth of 1 nm. All data were collected using a stop resolution of
1 nm and time per point of 0.5 s. A control spectrum obtained from the diluted
buffer was subtracted from the original data. CD readouts were converted to mean
residue ellipticity (M.R.E).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this paper are available from the corresponding author
upon reasonable request. A reporting summary for this article is available as a
Supplementary Information file. The source data underlying Figs. 2a, d, 4h, 5b–f, 6b, a
and Supplementary Figs. 3e, 4a, 5f, 6e, f, 7b, c are provided as a Source Data file. The X-
ray crystallographic coordinates and structure factor files for MFN2IM structures have
been deposited in the Protein Data Bank (PDB) under the following accession numbers:
6JFL for nucleotide-free MFN2IM, 6JFK for GDP-bound MFN2IM, and 6JFM for
MFN2IM(T111D).
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